Chronic Lymphocytic Leukemia: Expert Insights and Strategies for Refining Patient Care

This comprehensive program gathers insight from 5 experts to improve the skills of clinicians who treat patients with CLL featuring education across the disease spectrum enhanced by practical tools for applying new findings in the clinic. All aspects of this program are designed to complement each other and includes an Interactive Treatment Decision Aide expert-authored modules expert commentaries and downloadable slidesets.

Share

Program Content

Activities

CLL Molecular Considerations
How I Adapt CLL Treatment to Evolving Molecular Considerations
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 09, 2016

Expires: August 08, 2017

Treating Fit Patients With CLL
How I Treat Young, Fit Patients With Newly Diagnosed Non-del(17p) CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 29, 2016

Expires: September 28, 2017

Relapsed del(17p) CLL
What Is the Optimal Treatment for Patients With Relapsed del(17p) CLL?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: October 31, 2016

Expires: October 30, 2017

Assessing <i>IgHV</i> Mutations in CLL
Should You Use IgHV Mutation Status to Select Optimal Choice of Therapy for Your Patients With CLL?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 16, 2016

Expires: November 15, 2017

ASH 2016 Ibrutinib in CLL
CLL Studies Presented at the 2016 Hematology Meeting Confirm Ibrutinib’s Long-term Efficacy and Suggest Benefit From Second-line Agents
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 06, 2017

Expires: January 05, 2018

Ibrutinib-Refractory Non-del(17p) CLL
How I Manage Ibrutinib-Refractory Patients With CLL Without Del(17p)
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2017

Expires: April 12, 2018

Maintenance Therapy in CLL
What Is the Role of Maintenance Therapy in CLL?
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 16, 2017

Expires: May 15, 2018

Top 5 Abstracts in CLL
ASCO 2017: My Top 5 Most Interesting CLL Abstracts
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 22, 2017

Expires: June 21, 2018

Activities

Downloadable Slideset
Strategies for Managing Patients With Chronic Lymphocytic Leukemia: Expert Insights on the Evolving Clinical Treatment Landscape
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 03, 2016

Expires: November 02, 2017

Downloadable Slideset
Expert Recommendations for Optimizing Care of Patients With Chronic Lymphocytic Leukemia
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 15, 2017

Expires: June 14, 2018

Faculty

cover img faculity

Farrukh Awan, MD, MS

Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

cover img faculity

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

cover img faculity

Jeffrey A. Jones, MD, MPH

Associate Professor of Medicine
Section Head of CLL/HCL
Division of Hematology
The Ohio State University
Columbus, Ohio

cover img faculity

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

Genentech Roche Virology

Janssen Pharmacyclics

Pharmacyclics Inc